Patients facing a Huntington’s disease diagnosis have had little hope until recently, but new gene therapies show promise in slowing disease progression. For decades, treatment options have been limited to managing symptoms rather than slowing or stopping the disease itself. Now, an experimental therapy, AMT-130, shows the potential to slow functional decline by 75% at 36 months. For the 41,000 Americans who’ve received the diagnosis, and another 200,000 at risk of inheriting it, the news is potentially life-changing.
Slowing Progression, Extending Possibilities
Huntington’s disease is an inherited disorder that slowly erodes a person’s physical and cognitive abilities, and takes a severe toll on mental health. For generations, families have faced the illness with limited medical options.
The AMT-130 study offers the first glimpse of real change. By introducing an engineered virus, the treatment delivers a small slice of genetic material into brain cells, reducing production of the faulty protein that causes Huntington’s characteristic degeneration. In the study, AMT-130 treatment appeared to meaningfully slow disease progression, giving patients hope for a longer window of independence and improving quality of life.
Making Discoveries Accessible to All
Larger trials to confirm the promising findings are expected. If all goes well, AMT-130 could potentially become the first FDA-approved treatment to alter the course of Huntington’s disease. For those who have long faced the terrifying disease without treatment options, the moment marks long-awaited progress.
